LEGN Price Prediction Next Week
Analysis and Insights
To predict the stock price of LEGN for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
The current price of LEGN is $34.54, with a 14-day RSI of 47.14, indicating a neutral position. The MACD is slightly bearish at -0.44, suggesting potential short-term weakness. Support levels are at $33.29 (Fibonacci S1) and $31.66 (Fibonacci S2), while resistance is at $38.54 (Fibonacci R1) and $40.16 (Fibonacci R2).
News Sentiment:
- Lobbying Disclosure: LEGN disclosed $100,000 in lobbying efforts for Q4 2024, focusing on educating Congress about biotechnology's role in healthcare. This indicates proactive engagement but may not directly impact stock price.
- Institutional Activity: 108 institutional investors increased their holdings in LEGN, while 84 reduced their positions, showing moderate positive sentiment.
- Analyst Target: The average analyst target price for LEGN is $82.29, indicating significant upside potential.
Price Prediction:
Based on the technical indicators and news sentiment, LEGN is expected to trade between $33.50 and $35.50 next week. The stock may experience short-term volatility but is likely to remain stable near its current levels.
Recommendation:
Sell if the stock tests the lower support level of $33.50, as the technical indicators suggest limited upside potential in the short term.
LEGN Similar Chart Price Prediction
The price of LEGN is predicted to go up -7.41%, based on the high correlation periods with HAL. The similarity of these two price pattern on the periods is 92.66%.
LEGN
HAL
Down: -7.41%Similarity: 92.66%
LEGN Revenue Forecast
LEGN EPS Forecast
LEGN FAQs
What is LEGN revenue forecast for next quarter？
What is LEGN eps forecast for next quarter？
LEGN Analyst's Forecast
Edward Tenthoff
Piper Sandler
Buy
2024-12-30
Price Target
$78
Upside
+138.02%
Piper Sandler lowered the firm's Carvykti revenue forecast to $290M from $335M in Q4 and to $1.63B from $1.75B in 2025 as Legend Biotech (LEGN) and Johnson & Johnson (JNJ) work to build supply. Carvykti "remains the Gold Standard with demand far outpacing supply," the analyst tells investors in a research note. The firm says Legend and J&J are working to increase supply to 10,000 autologous doses by the end of 2025. Piper reiterates an Overweight rating on Legend Biotech with a $78 price target.
Qize Ding
Redburn Atlantic
Strong Buy
2024-10-08
Price Target
$86
Upside
+78.94%
